Editor

FRANCISCO  M GONZALEZ OTERO
fco_gonzalez
[+info]

Directorio Médico

address_bookVisite nuestro Directorio Médico, la más completa base de datos de especialistas iberoamericanos en Dermatología Pediátrica
ir al Directorio Médico

Escríbanos

mailComunicarse con nosotros, le responderemos tan pronto sea posible, leemos todos los correos recibidos. Haga clic aquí para ir a nuestro formulario de contacto
Página de Inicio arrow Artículos Científicos arrow Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel
Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel Imprimir E-Mail
Journal of Pediatric Hematology/Oncology:
October 2009 - Volume 31 - Issue 10 - pp 723-729

Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel
Mora, Jaume MD, PhD; Cruz, Cheeu Ofelia MD, PhD; Parareda, Andreu MD, PhD; de Torres, Carmen MD, PhD
Abstract
Aim of the Study: In this report we describe experience with gemcitabine-docetaxel in pediatric patients with relapsed or refractory sarcomas.

Patients and Methods: Ten relapsed/refractory pediatric sarcoma patients including 6 Ewing sarcoma, 2 synovial sarcoma, 1 osteosarcoma, and 1 undifferentiated sarcoma, were treated prospectively, in an outpatient setting, with gemcitabine 1000 mg/m2 over 90 minutes on day 1 and 8, and docetaxel 100 mg/m2 over 2 to 4 hours on day 8 of a 21-day cycle, as an investigational rescue therapy.

Results: The patients (ages 4 to 18) received a total of 70 cycles of therapy (median 6 cycles; range: 4 to 10 y). All symptomatic patients responded clinically to the new regimen. By Response Evaluation Criteria in Solid Tumors criteria, 4 (40%) patients had a complete response (CR), 1 (10%) had a partial response (PR), 3 (30%) had stable disease (SD), and 2 (20%) had a progressive disease (PD), which provides an objective response rate (CR+PR) of 50%. Median duration of response (CR+PR+SD) was 10 months (range: 6 to 32+ mo). Five out of the 10 patients (50%) are alive, with a median follow-up of 48 months from diagnosis. Mild toxicities (no grades 3 to 4) were encountered and managed in the ambulatory setting.

Conclusions: The gemcitabine-docetaxel regimen demonstrated antitumor activity against advanced pediatric (mainly Ewing) sarcomas, allowing for good quality of life. Evaluation in a large, formal phase 2 trials for Ewing patients is ongoing.
 
< Anterior   Siguiente >
[Volver]

Conferencias Científicas

Traemos a todos los especialistas, un repositorio de conferencias y charlas sobre temas de interés médico y formación de nuevas generaciones especialistas. Invitamos a visitar nuestra galería de Conferencias .